2Gloeckler Ries LA,Reichman ME,Lewis DR,et al.Cancer survival and incidence from the Surveillance,Epidemiology,and End Results (SEER) program[J].Oncologist,2003,8(6):541-552. 被引量：1
5[24]Paez JG, Janne PA, Lee Jc, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy.Science, 2004, 304:1497 被引量：1
6[25]Pao W, Miller V, Zakomski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers"and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA, 2004, 101 (36) : 13306 被引量：1
7[1]Wells A. The epidermal growth factor receptor (EGFR): A new target in cancer therapy. Signal, 2000, 1 (1) :4 被引量：1
9[3]Raben D, Helfrich BA, Chan D, et al. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin Oncol,2002, 29 (Suppl4) :37 被引量：1
10[4]Liu CY, Seen S. Gefitinib therapy for advanced non-small-cell lung cancer. Ann Pharmacother, 2003, 37 (11) :1644 被引量：1
